Skip header and navigation

Narrow By

   MORE

99 records – page 1 of 5.

Advances in DNA repair in cancer therapy

https://libcat.nshealth.ca/en/permalink/provcat32399
Lawrence Panasci, Raquel Aloyz, Moulay Alaoui-Jamali, editors. --New York, NY: Springer , c2013.
Available Online
View e-Book
Location
Online
This book deals with the emerging role of various DNA repair proteins and the regulatory elements which are implicated in cancer therapy such as DNA cross-linking agents, radiotherapy and bleomycin. The DNA repair genes discussed include those involved in BRCA/Rad51-related homologous recombinational repair, DNA-PK related nonhomologous endjoining and the nucleotide excision repair gene, ERCC1. Moreover, the role of regulatory genes such as PARP, ATR, telomerase, growth factor receptors and dow…
Available Online
View e-Book
Other Authors
Panasci, Lawrence
Aloyz, Raquel
Alaoui-Jamali, Moulay
Responsibility
Lawrence Panasci, Raquel Aloyz, Moulay Alaoui-Jamali, editors
Place of Publication
New York, NY
Publisher
Springer
Date of Publication
c2013
Physical Description
1 online resource (viii, 312 p. : 35 ill., 25 ill. in color)
Series Vol.
72
Series Title
Cancer drug discovery and development
ISBN
9781461447412
Subjects (MeSH)
Antineoplastic Agents - therapeutic use
DNA Repair
Neoplasms - drug therapy
Neoplasms - genetics
Subjects (LCSH)
Oncology
Abstract
This book deals with the emerging role of various DNA repair proteins and the regulatory elements which are implicated in cancer therapy such as DNA cross-linking agents, radiotherapy and bleomycin. The DNA repair genes discussed include those involved in BRCA/Rad51-related homologous recombinational repair, DNA-PK related nonhomologous endjoining and the nucleotide excision repair gene, ERCC1. Moreover, the role of regulatory genes such as PARP, ATR, telomerase, growth factor receptors and downstream kinase signalling is examined.
Contents
Repair of DNA interstrand cross-links produced by cancer chemotherapeutic drugs -- DNA-PK, a pharmacological target in cancer chemotherapy and radiotherapy -- Growth factor receptor signaling, DNA damage response, and cancer cell susceptibility to chemotherapy and relapses -- Relationship between DNA-repair genes, cellular radiosensitivity, and the response of tumors annd normal tissues to radiotherapy -- Important roles of ERCCI in DNA repair and targeted therapy -- The role of BRCA1 and BRCA2 in anticancer drug therepy -- DNA-PK in CLL chemotherapy -- Poly (ADP) ribose polymerase at the interface of DNA damage signaling and DNA repair -- Cellular protection against the antitumor drug bleomycin -- ATR as a therapeutic target -- Telomores, Telomerase, and DNA damage response in cancer therapy -- RAD51 is a key protein of DNA repair and homologous recombination in humans -- Index.
Format
e-Book
Location
Online
Less detail

ALERT – adverse late effects of cancer treatment. Volume 1, General concepts and specific precepts

https://libcat.nshealth.ca/en/permalink/provcat33390
Philip Rubin, Louis S. Constine, Lawrence B. Marks, editors. --Heidelberg: Springer , c2014.
Available Online
View e-Book
Location
Online
The literature on the late effects of cancer treatment is widely scattered in different journals since all major organ systems are affected and management is based on a variety of medical and surgical treatments. The aim of ALERT Adverse Late Effects of Cancer Treatment is to offer a coherent multidisciplinary approach to the care of cancer survivors. The central paradigm is that cytotoxic multimodal therapy results in a perpetual cascade of events that affects each major organ system different…
Available Online
View e-Book
Other Authors
Rubin, Philip
Constine, Louis S
Marks, Lawrence B
Responsibility
Philip Rubin, Louis S. Constine, Lawrence B. Marks, editors
Alternate Title
Adverse late effects of cancer treatment
Place of Publication
Heidelberg
Publisher
Springer
Date of Publication
c2014
Physical Description
1 online resource (xxiv, 311 pages)
Series
Medical radiology. Radiation oncology
Series Title
Medical radiology (Series)
ISBN
9783540723141 (electronic bk.)
9783540723134
Subjects (MeSH)
Antineoplastic Agents - adverse effects
Radiotherapy - adverse effects
Radiation Injuries
Subjects (LCSH)
Cancer - Treatment - Complications
Antineoplastic Agents - adverse effects
Radiotherapy - adverse effects
Abstract
The literature on the late effects of cancer treatment is widely scattered in different journals since all major organ systems are affected and management is based on a variety of medical and surgical treatments. The aim of ALERT Adverse Late Effects of Cancer Treatment is to offer a coherent multidisciplinary approach to the care of cancer survivors. The central paradigm is that cytotoxic multimodal therapy results in a perpetual cascade of events that affects each major organ system differently and is expressed continually over time. Essentially, radiation and chemotherapy are intense biologic modifiers that allow for cancer cure and cancer survivorship but accelerate senescence of normal tissues and increase the incidence of age-related diseases and second malignant tumors. Volume 1 of this two-volume work focuses on the general concepts and principles relevant to late effects and on the dynamic interplay of molecular, cytologic and histopathologic events that lead to altered physiologic and metabolic functions and their clinical manifestations. Chapters are also included on legal issues, economic aspects, nursing, psychological issues and quality of life.
Contents
Prologue: Surviving Cancer: SEER Statistics -- Biocontinuum of the Pathophysiology Paradigm -- Biophysiopathology of the Microvasculature and Microcirculation -- Molecular Mechanisms of Radiation Induced Injury -- Biodetection and Biointervention: Cytokine Pathways as a Rationale for Anti-Cytokine Interventions Post-Radiation -- Quantitative/Objective Analyses of RT-Induced Late Normal Tissue Injury Using Functional Imaging -- Biograding of Normal Tissue TNM Toxicity Taxonomy: Scoring the Adverse Effects of Cancer Treatment -- Understanding and Predicting Radiation-Associated Normal Tissue Injury: A Global and Historical Perspective -- Biotoxicity of Chemotherapy -- BioSurveillance and Longitudinal Lifelong Guidelines -- BioPediatric Complexities of Growth and Development -- BioGenetic and Host Implications -- Bioengineering of Irradiated Normal Tissues by Bone Marrow Stem Cells -- Radiotherapy-Induced Carcinogenesis and Leukemogenesis: Mechanisms and Quantitative Modeling -- The Bioepidemiology of MultiplePrimary Cancers -- Radiation-Related Second Primary Cancers: Clinical Perspectives -- The Psychosocial and Functional Impact of Radiation Therapy -- Nursing -- Economic Consequences of Late Effects -- Radiological and Nuclear Terrorism: Relevance to the Radiation Oncology and Biology Communities.
Format
e-Book
Location
Online
Less detail

ALERT – adverse late effects of cancer treatment. Volume 2, Normal tissue specific sites and systems

https://libcat.nshealth.ca/en/permalink/provcat33418
Philip Rubin, Louis S. Constine, Lawrence B. Marks, editors. --Heidelberg: Springer , c2014.
Available Online
View e-Book
Location
Online
The literature on the late effects of cancer treatment is widely scattered in different journals since all major organ systems are affected and management is based on a variety of medical and surgical treatments. The aim of ALERT Adverse Late Effects of Cancer Treatment is to offer a coherent multidisciplinary approach to the care of cancer survivors. The central paradigm is that cytotoxic multimodal therapy results in a perpetual cascade of events that affects each major organ system different…
Available Online
View e-Book
Other Authors
Rubin, Philip
Constine, Louis S
Marks, Lawrence B
Responsibility
Philip Rubin, Louis S. Constine, Lawrence B. Marks, editors
Alternate Title
Adverse late effects of cancer treatment
Place of Publication
Heidelberg
Publisher
Springer
Date of Publication
c2014
Physical Description
1 online resource (xx, 700 pages)
Series
Medical radiology. Radiation oncology
Series Title
Medical radiology (Series)
ISBN
9783540758631 (electronic bk.)
9783540758624
Subjects (MeSH)
Antineoplastic Agents - adverse effects
Radiotherapy - adverse effects
Radiation Injuries
Subjects (LCSH)
Cancer - Treatment - Complications
Neoplasms - therapy - complications
Abstract
The literature on the late effects of cancer treatment is widely scattered in different journals since all major organ systems are affected and management is based on a variety of medical and surgical treatments. The aim of ALERT Adverse Late Effects of Cancer Treatment is to offer a coherent multidisciplinary approach to the care of cancer survivors. The central paradigm is that cytotoxic multimodal therapy results in a perpetual cascade of events that affects each major organ system differently and is expressed continually over time. Essentially, radiation and chemotherapy are intense biologic modifiers that allow for cancer cure and cancer survivorship but accelerate senescence of normal tissues and increase the incidence of age-related diseases and second malignant tumors. Volume 2 of this two-volume work comprehensively documents potential late effects in all the normal tissue anatomic sites in the human body. The detection, diagnosis, management and prevention of effects are all considered in detail, and prognostic outcomes are discussed. Radiation risk factors and interactions with chemotherapy effects are clearly presented. The text is accompanied by numerous supportive illustrations and tables.
Contents
Brain and Cranial Nerves -- Spinal Cord and Peripheral Nervous System -- Neuroendocrine Complications of Radiation and Cancer Therapy -- Eye and Orbit -- Radiation-Induced Ototoxicity -- Late Oral Adverse Effects of Cancer Treatments -- Upper Respiratory and Digestive System: Pharynx, Larynx, and Xerostomia -- Thyroid -- Skin Surface, Dermis, and Wound Healing -- Breast Cancer -- Lung -- Heart, Coronary Arteries, Aorta and Great Vessels, Arteries and Veins, Microcirculation -- Esophagus -- Stomach, Small and Large Intestines -- Liver -- Adverse Late Effects of Radiation Treatment in the Pancreas -- Kidney and Ureter -- Urinary Bladder -- Prostate, Seminal Vesicle, Penis, and Urethra -- The Testes -- Ovary, Uterus (Fallopian Tube, Cervix), Vagina, and Vulva -- Radiation Induced Rectal Toxicity -- Musculoskeletal System: Growing Endochondral Bone, Mature Osseous, Muscle (Striated), and Soft Tissue Mesenchyme -- Hematopoietic System -- Late Effects of Hematopoietic Cell Transplantation Including Total Body Irradiation -- Lymph Nodes, Thymus, Spleen, and Lymphatics.
Format
e-Book
Location
Online
Less detail

Antiangiogenic Agents in Cancer Therapy

https://libcat.nshealth.ca/en/permalink/provcat40632
edited by Beverly A. Teicher, Lee M. Ellis. (2nd ed.) --Totowa, NJ: Humana Press , c2008.
Available Online
View e-Book
Location
Online
Antiangiogenesis remains a dynamic and evolving field in oncology. New therapeutic targets continue to emerge followed by the rapid development of new therapeutic agents to be investigated in clinical trials. Optimizing the therapeutic potential of antiangiogenic agents in combination with the other therapies in the armamentarium to fight cancer will be an on-going challenge. Antiangiogenic Agents in Cancer Therapy, Second Edition provides a current, up-dated perspective on the state of the art…
Available Online
View e-Book
Other Authors
Teicher, Beverly A
Ellis, Lee M
Responsibility
edited by Beverly A. Teicher, Lee M. Ellis
Edition
2nd ed.
Place of Publication
Totowa, NJ
Publisher
Humana Press
Date of Publication
c2008
Physical Description
1 online resource (xviii, 559 p. : ill.)
Series Title
Cancer drug discovery and development
ISBN
9781597451840
9781588298706 (print ed.)
Subjects (MeSH)
Angiogenesis Inhibitors - therapeutic use
Antineoplastic Agents - therapeutic use
Neoplasms - drug therapy
Neovascularization, pathologic - drug therapy
Abstract
Antiangiogenesis remains a dynamic and evolving field in oncology. New therapeutic targets continue to emerge followed by the rapid development of new therapeutic agents to be investigated in clinical trials. Optimizing the therapeutic potential of antiangiogenic agents in combination with the other therapies in the armamentarium to fight cancer will be an on-going challenge. Antiangiogenic Agents in Cancer Therapy, Second Edition provides a current, up-dated perspective on the state of the art of angiogenesis and therapy with a compendium of scientific findings and approaches to the study of angiogenesis in cancer. Leaders in the field present chapters on such topics as the environmental influences and the genetic and physiologic abnormalities that mediate angiogenesis and its role in the progression of malignant disease, working models of tumor angiogenesis, and the role of angiogenesis inhibition in the therapy of malignant disease in humans. Comprehensive and cutting-edge, Antiangiogenic Agents in Cancer Therapy, Second Edition is an ideal, valuable guide to the most recent advances in the field, and a collection that will be useful for many years to come.
Contents
Part I. Basic Biology of Angiogenesis -- Vascular Endothelial Growth Factor Family and Its Receptors -- The Cycle Between Angiogenesis, Perfusion, and Hypoxia in Tumors -- The Role of Integrins in Tumor Angiogenesis -- Tumor Endothelial Cell Abnormalities -- The Extracellular Matrix and VEGF Processing -- Endothelial Precursor Cells -- Role of Pericytes in Angiogenesis -- Newer Vascular Targets -- Chemokines in Angiogenesis -- Angiopoietin/Tie2 Signaling Regulates Tumor Angiogenesis -- Imaging Angiogenesis -- Tumor Blood Vessels -- Lymphatic System in the Pathology of Cancer -- Part II. Translational Research in Tumor Angiogenesis -- VEGF in the Adult -- Normalization of Tumor Vasculature and Microenvironment -- Metronomic Low-Dose Antiangiogenic Chemotherapy in Mice and Man -- Small-Molecule Vascular Disrupting Agents in Cancer Therapy -- Normalization of Tumor Vasculature and Improvement of Radiation Response by Antiangiogenic Agents -- Challenges in Translating Antiangiogenic Therapy from the Bench to Bedside -- Regulation of Angiogenesis in Cancer and Its Therapeutic Implications -- Part III. Antiangiogenic Therapy in the Clinical Trial Results and Future Directions -- Angiogenesis and Angiogenesis Inhibition in Sarcomas -- Antiangiogenesis Agents in Colorectal Cancer -- Antiangiogenic Therapy for Primary CNS Tumors -- Angiogenesis Inhibitors for the Treatment of Lung Cancer -- Antiangiogenic Therapy of Renal Cell Carcinoma -- Antiangiogenesis Therapies in Gynecologic Malignancies -- Antiangiogenic Agents in Myeloid Malignancies -- Angiogenesis in Malignant and Non-Malignant Pediatric Tumors -- Prognostic and Predictive Significance of Surrogate Biomarkers of Angiogenesis -- Endpoints for the Determination of Efficacy of Antiangiogenic Agents in Clinical Trials -- The Role of Imaging in the Clinical Development of Antiangiogenic Agents.
Format
e-Book
Location
Online
Less detail

Camptothecins in Cancer Therapy

https://libcat.nshealth.ca/en/permalink/provcat28891
edited by Val R. Adams, Thomas G. Burke. --Totowa, NJ: Humana Press , c2005.
Available Online
View e-Book
Location
Online
Available Online
View e-Book
Author
Adams, Val R
Other Authors
Burke, Thomas G
Responsibility
edited by Val R. Adams, Thomas G. Burke
Place of Publication
Totowa, NJ
Publisher
Humana Press
Date of Publication
c2005
Series Title
Cancer drug discovery and development
ISBN
9781592598663
Subjects (MeSH)
Camptothecin - pharmacology
Camptothecin - therapeutic use
Neoplasms - drug therapy
Antineoplastic Agents, Phytogenic - therapeutic use
Subjects (LCSH)
Oncology
Pharmacy
Format
e-Book
Location
Online
Less detail

Cancer and Cardiovascular Disease : A Concise Clinical Atlas

https://libcat.nshealth.ca/en/permalink/provcat42613
Syed Wamique Yusuf, Jose Banchs, editors. --Cham: Springer , c2018.
Available Online
View e-Book
Location
Online
The atlas provides a clear, concise, yet comprehensive review of common cardiovascular diseases occurring in patients with cancer. Cancer and cardiovascular disease are the two most common conditions worldwide. In clinical practice we frequently encounter patients who have established cardiovascular disease and subsequently develop cancer or are survivors of cancer with subsequent cardiovascular complications related to chemotherapy and or radiation. Most of the chapters are case based, followe…
Available Online
View e-Book
Other Authors
Yusuf, Syed Wamique
Banchs, Jose
Responsibility
Syed Wamique Yusuf, Jose Banchs, editors
Place of Publication
Cham
Publisher
Springer
Date of Publication
c2018
Physical Description
1 online resource (xii, 212 p.) : 351 illus., 198 illus. in color
ISBN
9783319620886
9783319620862 (print ed.)
9783319620879 (print ed.)
Subjects (MeSH)
Cardiovascular Diseases - complications
Neoplasms - complications
Antineoplastic Agents - adverse effects
Specialty
Cardiology
Medical Oncology
Abstract
The atlas provides a clear, concise, yet comprehensive review of common cardiovascular diseases occurring in patients with cancer. Cancer and cardiovascular disease are the two most common conditions worldwide. In clinical practice we frequently encounter patients who have established cardiovascular disease and subsequently develop cancer or are survivors of cancer with subsequent cardiovascular complications related to chemotherapy and or radiation. Most of the chapters are case based, followed by images and a discussion on current (evidence based, wherever available) investigations and treatment outline.
Contents
1. Global Burden of Cancer and Cardiovascular Disease -- 2. Utility of Cardiac Ultrasound Imaging in Oncology, a Case Based Illustration -- 3. Cancer Treatment-Related Cardiotoxicity: Role of Cardiovascular Magnetic Resonance Imaging -- 4. Imaging to Diagnose Myocarditis, Cardiomyopathy, Tumor and Thrombus -- 5. Takotsubo Syndrome and Cancer -- 6. Mechanism and Prevention of Cardiomyopathy Due to Chemotherapy -- 7. Radiation Related Cardiovascular Disease -- 8. Acute Coronary Syndrome in Patients with Cancer -- 9. Arterial Complications in Patients with Cancer -- 10. Carotid Artery Disease in Patients with Cancer -- 11. Venous Diseases in Malignancy -- 12. Cardiac Masses -- 13. Surgical Treatment for Cardiac Sarcomas -- 14. Cardiac Arrhythmia and Device Management in Patients with Cancer -- 15. Endocarditis -- 16. Pericardial Disease, Constrictive Pericarditis and Restrictive Cardiomyopathy in Patients with Cancer -- 17. Exercise Therapy and Cardiovascular Benefits in Patients with Cancer.
Format
e-Book
Publication Type
Atlas
Location
Online
Less detail

Cancer Chemotherapy in Clinical Practice

https://libcat.nshealth.ca/en/permalink/provcat30817
Terry Priestman. (2nd ed.) --London: Springer , c2012.
Available Online
View e-Book
Location
Online
The last decade has seen many dramatic changes in cancer chemotherapy, with the introduction of a number of new forms of treatment as well as important developments in the more traditional fields of cytotoxic and hormonal therapy. Now in its second edition, this book summarizes the whole range of systemic cancer therapies and their clinical applications, taking into account new drugs and the emerging concept of personalized therapy. Intended as an introductory text for junior doctors, nurses a…
Available Online
View e-Book
Author
Priestman, Terrence
Responsibility
Terry Priestman
Edition
2nd ed.
Place of Publication
London
Publisher
Springer
Date of Publication
c2012
Physical Description
1 online resource (xiii, 177 p. : 15 ill., 3 ill. in color)
ISBN
9780857297273
Subjects (MeSH)
Neoplasms - drug therapy
Antineoplastic Agents - therapeutic use
Subjects (LCSH)
Oncology
Pharmacy
Abstract
The last decade has seen many dramatic changes in cancer chemotherapy, with the introduction of a number of new forms of treatment as well as important developments in the more traditional fields of cytotoxic and hormonal therapy. Now in its second edition, this book summarizes the whole range of systemic cancer therapies and their clinical applications, taking into account new drugs and the emerging concept of personalized therapy. Intended as an introductory text for junior doctors, nurses and medical students, Cancer Chemotherapy in Clinical Practice is divided into three sections: The Theoretical Basis of Cancer Chemotherapy: following a historical introduction the different treatment modalities are explained in the context of basic tumor biology Practical Aspects of Chemotherapy: covering dosing and drug delivery together with an extensive discussion of possible side-effects and their management Chemotherapy in the Management of Cancer: explaining the place of drug treatment and the outcomes that can be expected from chemotherapy in all the major cancers.
Contents
1. The Theoretical Basis of Cancer Chemotherapy -- 2. Practical aspects of chemotherapy -- 3. Part III: Chemotherapy in the management of cancer
Format
e-Book
Location
Online
Less detail

Cancer Drug Resistance

https://libcat.nshealth.ca/en/permalink/provcat28300
edited by Beverly A. Teicher. --Totowa, NJ: Humana Press , c2006.
Available Online
View e-Book
Location
Online
Available Online
View e-Book
Author
Teicher, Beverly A
Responsibility
edited by Beverly A. Teicher
Place of Publication
Totowa, NJ
Publisher
Humana Press
Date of Publication
c2006
Series Title
Cancer drug discovery and development
ISBN
9781597450355
Subjects (MeSH)
Antineoplastic Agents - therapeutic use
Drug Resistance, Neoplasm
Subjects (LCSH)
Oncology
Pharmacy
Format
e-Book
Location
Online
Less detail

Cancer immunotherapy : immune suppression and tumor growth

https://libcat.nshealth.ca/en/permalink/provcat27591
Pendergast, George C. --Amsterdam, Netherlands: Elsevier Academic Press , 2007.
Available Online
View e-Book
Location
Online
Available Online
View e-Book
Author
Pendergast, George C
Other Authors
Jaffee, Elizabeth M
Place of Publication
Amsterdam, Netherlands
Publisher
Elsevier Academic Press
Date of Publication
2007
Physical Description
409 p.
ISBN
9780080521855
Subjects (MeSH)
Antineoplastic Agents - therapeutic use
Immunotherapy
Neoplasms - therapy
Contents
Cancer immunoediting: from immune surveillance to immune escape / Ryungsa Kim -- Immunosurveillance: innate and adaptive antitumor immunity / Masahisa Jinushi and Glenn Dranoff -- Cytokine regulation of immune tolerance to tumors / Ming O. Li and Richard A. Flavell -- Immunological sculpting: natural killer cell receptors and ligands / David A. Sallman and Julie Y. Djeu -- Immune escape: immunosuppressive networks / Shuang Wei, Alfred Chang, and Weiping Zou -- Cytotoxic chemotherapy in clinical treatment of cancer / Rajesh Thirumaran, George C. Prendergast, and Paul B. Gilman -- Targeted therapeutics in cancer treatment / Colin D. Weekes and Manuel Hidalgo -- Concepts in pharmacology and toxicology / Richard A. Westhouse and Bruce D. Car -- Cancer immunotherapy: challenges and opportunities / Andrew J. Lepisto, John R. McKolanis, and Olivera J. Finn -- Cancer vaccines / Freda K. Stevenson ... [et al.] -- Immunotherapy and cancer therapeutics: why partner? / Leisha A. Emens and Elizabeth M. Jaffee -- Immune stimulatory features of classical chemotherapy / Robbert G. van der Most, Anna K. Nowak, and Richard A. Lake -- Dendritic cells and coregulatory signals: immune checkpoint blockade to stimulate immunotherapy / Drew Pardoll -- Regulatory T cells in tumor immunity: role of toll-like receptors / Rong-Fu Wang -- Tumor-associated macrophages in cancer growth and progression / Alberto Mantovani, Paola Allavena and Antonio Sica -- Tumor-associated myeloid-derived suppressor cells / Stephanie K. Bunt ... [et al.] -- Programmed death ligand-1 and galectin-1: pieces in the puzzle of tumor-immune escape / Gabriel A. Rabinovich and Thomas F. Gajewski -- Indoleamine 2,3-dioxygenase in immune escape: regulation and therapeutic inhibition / Alexander J. Muller and George C. Prendergast -- Arginase, nitric oxide synthase, and novel inhibitors of L-arginine metabolism in immune modulation / Susanna Mandruzzato, Simone Mocellin, and Vincenzo Bronte.
Format
e-Book
Location
Online
Less detail

Cancer Management in Man : Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures

https://libcat.nshealth.ca/en/permalink/provcat28897
edited by Boris R. Minev. --Dordrecht ; New York: Springer Science+Business Media , c2011.
Available Online
View e-Book
Location
Online
Available Online
View e-Book
Author
Minev, Boris R
Responsibility
edited by Boris R. Minev
Place of Publication
Dordrecht ; New York
Publisher
Springer Science+Business Media
Date of Publication
c2011
Series Vol.
13
Series Title
Cancer growth and progression
ISBN
9789048197040
Subjects (MeSH)
Antineoplastic Agents - therapeutic use
Neoplasms - drug therapy
Neoplasms - therapy
Subjects (LCSH)
Oncology
Format
e-Book
Location
Online
Less detail

Cancer Proteomics : From Bench to Bedside

https://libcat.nshealth.ca/en/permalink/provcat40631
edited by Sayed S. Daoud. --Totowa, NJ: Humana Press , c2008.
Available Online
View e-Book
Location
Online
Over the past 20 years or so, there have been tremendous advances in our understanding of how normal cells transform to cancer and the importance of signaling pathways in cancer initiation and progression. Therefore, proteomics technologies must be improved for more global analysis of protein content of cells, tissues and body fluids as well as the posttranslational modifications to allow for proper detections and validation. In Cancer Proteomics, the authors collectively provide the current st…
Available Online
View e-Book
Other Authors
Daoud, Sayed S
Responsibility
edited by Sayed S. Daoud
Place of Publication
Totowa, NJ
Publisher
Humana Press
Date of Publication
c2008
Physical Description
1 online resource (xii, 264 p. : 5 illus. in color)
Series Title
Cancer drug discovery and development
ISBN
9781597451697
9781588298584 (print ed.)
Subjects (MeSH)
Antineoplastic Agents
Biomarkers, Tumor
Neoplasms
Proteomics - methods
Abstract
Over the past 20 years or so, there have been tremendous advances in our understanding of how normal cells transform to cancer and the importance of signaling pathways in cancer initiation and progression. Therefore, proteomics technologies must be improved for more global analysis of protein content of cells, tissues and body fluids as well as the posttranslational modifications to allow for proper detections and validation. In Cancer Proteomics, the authors collectively provide the current status of proteomics in cancer therapy and offers the existing technologies used in proteomics that allow for protein profiling and for the identification of druggable targets in human samples. Mass spectrometry based protein characterization and protein microarrays hold great promise of predicting response to specific drugs in cancer therapy. Insightful to the reader with broad perspectives on topics related to the use of proteomic strategies in cancer therapy, Cancer Proteomics offers anticipated challenges that may arise from its application in daily practice.
Contents
Part I. Proteomics Technologies -- Current and Emerging Mass Spectrometry Instrumentation and Methods for Proteomic Analyses -- Part II. Cell Signaling Proteomics -- Integration of Genomics and Proteomics in Dissecting p53 Signaling -- Proteomic Profiling of Tyrosine Kinases as Pharmacological Endpoints for Targeted Cancer Therapy -- Part III. Tumor Proteomics -- Oncoproteomics for Personalized Management of Cancer -- Application of Serum and Tissue Proteomics to Understand and Detect Solid Tumors -- Insight on Renal Cell Carcinoma Proteome -- Proteomics in Lung Cancer -- Proteomic Strategies of Therapeutic Individualization and Target Discovery in Acute Myeloid Leukemia -- New Tumor Biomarkers: Practical Considerations Prior to Clinical Application -- Part IV. Bioinformatics and Regulatory Aspects of Proteomics -- Annotating the Human Proteome: From Establishing a Parts List to a Tool for Target Identification -- Regulatory Issues in the Co-Development of Oncology Drugs and Proteomic Tests: An Overview.
Format
e-Book
Location
Online
Less detail

Cancer Stem Cells : Novel Concepts and Prospects for Tumor Therapy

https://libcat.nshealth.ca/en/permalink/provcat40599
O.D. Wiestler, B. Haendler, D. Mumberg, editors. --Berlin, Heidelberg: Springer , c2007.
Available Online
View e-Book
Location
Online
This book describes the recent developments in the emerging field of cancer stem cells. Their possible impact for the identification of novel treatment paradigms for cancer are discussed.
Available Online
View e-Book
Other Authors
Wiestler, O.D
Haendler, B
Mumberg, D
Other Authors
Ernst Schering Research Foundation
Responsibility
O.D. Wiestler, B. Haendler, D. Mumberg, editors
Place of Publication
Berlin, Heidelberg
Publisher
Springer
Date of Publication
c2007
Physical Description
1 online resource (xvi, 263 p.)
Series Vol.
2006/5
Series Title
Springer Series on Biofilms
Ernst Schering Foundation Symposium Proceedings
ISBN
9783540708537
9783540708520 (print ed.)
ISSN
0947-6075
Subjects (MeSH)
Antineoplastic Agents - pharmacology
Neoplasms - prevention & control
Neoplastic Stem Cells - drug effects
Neoplastic stem cells - pathology
Signal transduction - physiology
Abstract
This book describes the recent developments in the emerging field of cancer stem cells. Their possible impact for the identification of novel treatment paradigms for cancer are discussed.
Contents
Niche for Normal and Cancer Stem Cells -- c-Myc and Activated Ras During Skin Tumorigenesis: Cooperation at the Cancer Stem Cell Level? -- Wnt Signaling in Stem Cells and Lung Cancer -- Bone Morphogenetic Proteins Regulate Tumorigenicity in Human Glioblastoma Stem Cells -- Strategies to Induce Nuclear Reprogramming -- The Intestinal Stem Cell Niche Studied Through Conditional Transgenesis -- The Migrating Cancer Stem Cells Model - A Conceptual Explanation of Malignant Tumour Progression -- Bone Marrow Niche and Leukemia -- Breast Stem Cells and Cancer -- Prostate Cancer Stem Cells: A Target for New Therapies -- The Hedgehog Signaling Network, Mammary Stem Cells, and Breast Cancer: Connections and Controversies -- Strategies to Eliminate Cancer Stem Cells -- DNA Repair in Stem Cell Maintenance and Conversion to Cancer Stem Cells -- Tumorigenic Epithelial Stem Cells and Their Normal Counterparts.
Format
e-Book
Publication Type
Congress
Location
Online
Less detail

Cardiac Management of Oncology Patients : Clinical Handbook for Cardio-Oncology

https://libcat.nshealth.ca/en/permalink/provcat39229
Gonzalo Baron Esquivias, Riccardo Asteggiano, editors. --Cham: Springer , c2015.
Available Online
View e-Book
Location
Online
In recent years, progress in oncologic therapy has achieved important goals and a consequent prognostic improvement for patients with malignancy, but cardiac toxicity is often a concern and can have long-term functional or structural effects on the heart. This book is written for the cardiologist working in a clinical environment without support from a specific specialized cardio-oncologist team, and who are called to perform a clinical consultation to evaluate a cardiac condition and the eligi…
Available Online
View e-Book
Other Authors
Baron Esquivias, Gonzalo
Asteggiano, Riccardo
Responsibility
Gonzalo Baron Esquivias, Riccardo Asteggiano, editors
Place of Publication
Cham
Publisher
Springer
Date of Publication
c2015
Physical Description
1 online resource (ix, 259 p. : 65 illus., 58 illus. in color)
ISBN
9783319158082
9783319158075 (print ed.)
Subjects (MeSH)
Antineoplastic Agents - toxicity
Heart diseases - etiology
Heart Diseases - therapy
Neoplasms - complications
Abstract
In recent years, progress in oncologic therapy has achieved important goals and a consequent prognostic improvement for patients with malignancy, but cardiac toxicity is often a concern and can have long-term functional or structural effects on the heart. This book is written for the cardiologist working in a clinical environment without support from a specific specialized cardio-oncologist team, and who are called to perform a clinical consultation to evaluate a cardiac condition and the eligibility for a patient to receive chemotherapy or radiotherapy. Cardiac Management of Oncology Patients: Clinical Handbook for Cardio-Oncology is also designed for oncologists and cardiologists to evaluate if a cancer treatment has produced toxic effects on a patient who has either recently or historically been treated with chemo or radiotherapy. The reader will discover more about the cardiac damage potentially created by the oncologic therapy that they are considering for the treatment of their patients.
Contents
1 Introduction -- 2 Physiopathology and Toxic Heart Effects of Chemotherapy Drugs -- 3 Radiotherapy Heart Effects -- 4 Cardiac Imaging Technology in Cardio-oncology -- 5 Evaluation of the Oncologic Patient Before, During, and After Chemotherapy -- 6 Specific Clinic Problems in Cancer Therapy Cardiac Toxicity Complications -- 7 Synthetic Tables.
Format
e-Book
Location
Online
Less detail

Cardio-Oncology : The Clinical Overlap of Cancer and Heart Disease

https://libcat.nshealth.ca/en/permalink/provcat41453
Gretchen G. Kimmick, Daniel J. Lenihan, Douglas B. Sawyer, Erica L. Mayer, Dawn L. Hershman, editors. --Cham: Springer , 2017.
Available Online
View e-Book
Location
Online
Co-edited and written by an interdisciplinary team of experts in oncology and cardiology, this book is a clinically useful resource on these overlapping topics: Cardiac complications in patients receiving cancer therapy; The treatment of cancer in patients with cardiovascular disease; The treatment of cardiovascular disease in patients with cancer. When relevant to medical practice, epidemiology and basic science are also included in the discussion and each chapter is written by an oncologist a…
Available Online
View e-Book
Other Authors
Kimmick, Gretchen G
Lenihan, Daniel J
Sawyer, Douglas B
Mayer, Erica L
Hershman, Dawn L
Responsibility
Gretchen G. Kimmick, Daniel J. Lenihan, Douglas B. Sawyer, Erica L. Mayer, Dawn L. Hershman, editors
Place of Publication
Cham
Publisher
Springer
Date of Publication
2017
Physical Description
1 online resource (xv, 319 pages) : 55 illus., 49 illus. in color
ISBN
9783319430966
9783319430942 (print ed.)
Subjects (MeSH)
Antineoplastic Agents - adverse effects
Cardiotoxicity - complications
Cardiovascular Diseases - complications
Cardiovascular Diseases - prevention & control
Neoplasms - complications
Neoplasms - drug therapy
Abstract
Co-edited and written by an interdisciplinary team of experts in oncology and cardiology, this book is a clinically useful resource on these overlapping topics: Cardiac complications in patients receiving cancer therapy; The treatment of cancer in patients with cardiovascular disease; The treatment of cardiovascular disease in patients with cancer. When relevant to medical practice, epidemiology and basic science are also included in the discussion and each chapter is written by an oncologist and a cardiologist. Additionally, the chapters follow a similar format to make the book truly interdisciplinary, user-friendly, and clinically applicable to specialists and non-specialists who care for patients with both cancer and cardiovascular disease.
Contents
1. Epidemiology of Cardio-Oncology -- 2. Cardiotoxicity of Anticancer Therapies -- 3. Screening and Monitoring for Cardiotoxicity During Cancer Treatment -- 4. Management of Chemotherapy-Associated Cardiomyopathy -- 5. Treatment of Hypertension in Patients Receiving Cancer Therapy -- 6. Preoperative and Pre-transplant Cardiac Evaluation in the Cancer Patient -- 7. Radiation Therapy and Cardiotoxicity -- 8. Management of Patients with Coronary Disease and Cancer: Interactions Between Cancer, Cancer Treatment, and Ischemia -- 9. Vascular Complications of Cancer and Cancer Therapy -- 10. Breast Cancer Cardio-Oncology -- 11. Cardiac Toxic Chemotherapy and Cancer Survivorship -- 12. Geriatric Cardio-oncology -- 13. Future Clinical and Professional Directions in Cardio-oncology.
Format
e-Book
Location
Online
Less detail

Checkpoint Controls and Targets in Cancer Therapy

https://libcat.nshealth.ca/en/permalink/provcat29742
edited by Zahid H. Siddik. --Totowa, NJ: Humana Press , c2009.
Available Online
View e-Book
Location
Online
Available Online
View e-Book
Author
Siddik, Zahid H
Responsibility
edited by Zahid H. Siddik
Place of Publication
Totowa, NJ
Publisher
Humana Press
Date of Publication
c2009
Series Title
Cancer drug discovery and development
ISBN
9781607611783
Subjects (MeSH)
Antineoplastic Agents - pharmacology
Cell Cycle Checkpoints
Cell Cycle - drug effects
Neoplasms - drug therapy
Format
e-Book
Location
Online
Less detail

Chemotherapy and immunotherapy guidelines and recommendations for practice

https://libcat.nshealth.ca/en/permalink/provcat43752
edited by MiKaela Olsen, Kristine B. LeFebvre, and Kelly J. Brassil. --Pittsburgh, PA: Oncology Nursing Society , c2019.
Available Online
View e-Book
Location
Online
Available Online
View e-Book
Other Authors
Olsen, MiKaela
Responsibility
edited by MiKaela Olsen, Kristine B. LeFebvre, and Kelly J. Brassil.
Alternate Title
Chemotherapy and immunotherapy guidelines & recommendations for practice
Place of Publication
Pittsburgh, PA
Publisher
Oncology Nursing Society
Date of Publication
c2019
Physical Description
1 online resource
ISBN
9781635930214
Subjects (MeSH)
Antineoplastic Agents
Immunotherapy
Neoplasms - nursing
Neoplasms - therapy
Specialty
Medical Oncology
Pharmacology
Format
e-Book
Publication Type
Practice Guideline
Location
Online
Less detail

Chemotherapy and Immunotherapy in Urologic Oncology : A Guide for the Advanced Practice Provider

https://libcat.nshealth.ca/en/permalink/provcat46364
Edouard J. Trabulsi, Costas D. Lallas, Anne E. Lizardi-Calvaresi, editors. --Cham: Springer , c2021.
Available Online
View e-Book
Access
NEW Springer 2021
Location
Online
This book is designed to familiarize clinical practitioners in systemic therapy options and medical management of urologic malignancies including prostate cancer, bladder and upper tract urothelial carcinoma, and renal cell carcinoma. Organized by organ system, the text highlights new therapies such as novel forms of androgen deprivation, cytotoxic chemotherapy, immune check point and immunomodulatory agents, and targeted therapies. Written by experts in the field, the book also reviews current…
Available Online
View e-Book
Other Authors
Trabulsi, Edouard J.
Lallas, Costas D.
Lizardi-Calvaresi, Anne E.
Responsibility
Edouard J. Trabulsi, Costas D. Lallas, Anne E. Lizardi-Calvaresi, editors
Place of Publication
Cham
Publisher
Springer
Date of Publication
c2021
Physical Description
1 online resource (xiv, 307 p.) : 22 illus., 19 illus. in color
ISBN
9783030520212
9783030520205 (Print ed.)
9783030520229 (Print ed.)
Subjects (MeSH)
Antineoplastic Agents - therapeutic use
Urologic Neoplasms - drug therapy
Immunotherapy - methods
Specialty
Medical Oncology
Pharmacology
Regenerative Medicine
Urology
Abstract
This book is designed to familiarize clinical practitioners in systemic therapy options and medical management of urologic malignancies including prostate cancer, bladder and upper tract urothelial carcinoma, and renal cell carcinoma. Organized by organ system, the text highlights new therapies such as novel forms of androgen deprivation, cytotoxic chemotherapy, immune check point and immunomodulatory agents, and targeted therapies. Written by experts in the field, the book also reviews current chemotherapy and immunotherapy regimens for genitourinary malignancies and discusses indications, outcomes, and toxicities, as well as clinical trial concepts. Each of the book’s chapters offers a bulleted box of clinical pearls on the particular role of the APP. Chemotherapy and Immunotherapy in Urologic Oncology: A Guide for the Advanced Practice Provider is a resource for urologists, uro-radiologists, medical clinicians and family practitioners alike, familiarizing its audiences with systemic therapy regimens for urologic malignancies, as well as their expected outcomes and side effects. .
Contents
Introduction: Integration of APP into Urologic Oncology Practice -- Part I. Prostate Cancer -- Overview and Active Surveillance of Prostate Cancer -- Monitoring and Managing Men Following Initial Treatment of Prostate Cancer -- Radical Prostatectomy and Survivorship after Radical Prostatectomy -- Multimodal Treatment Plans in Prostate Cancer -- Radiotherapy for Prostate Cancer -- Androgen Deprivation Treatment -- Second Generation Androgen Targeted Agents -- Chemotherapy and prostate cancer -- Radiopharmaceuticals for Prostate Cancer -- Immunotherapy and Novel Agents on the Horizon for the Treatment of Prostate Cancer -- Part II. Bladder Cancer -- Bladder Cancer: Overview, Epidemiology, Initial Presentation and Diagnosis -- Intravesical Therapy for Non Muscle Invasive Urothelial Carcinoma -- Bladder Cancer: Muscle Invasive Disease, Neoadjuvant Chemotherapy, and Radical Cystectomy -- Chemoradiation Bladder Preservation -- Metastatic Bladder Cancer and the Use of Cisplatin Chemotherapy -- Immunotherapy for Metastatic Urothelial Cancer -- Novel and experimental Strategies in the Treatment of Metastatic Urothelial Carcinoma -- Upper Tract Urothelial Carcinoma -- Part III. Kidney Cancer -- Kidney Cancer and Its Treatment -- Targeted Therapies for Treatment of Metastatic Renal Cell Carcinoma -- Immune Therapies for Metastatic Kidney Cancer -- Novel Therapies for Renal Cell Carcinoma -- Part IV. Other Malignancies -- Testicular Cancer -- Penile Cancer.
Access
NEW Springer 2021
Format
e-Book
Location
Online
Less detail

Chemotherapy and Pharmacology for Leukemia in Pregnancy : Guidelines and Strategies for Best Practices

https://libcat.nshealth.ca/en/permalink/provcat46361
Carolina Witchmichen Penteado Schmidt, Kaléu Mormino Otoni, editors. --Cham: Springer , c2021.
Available Online
View e-Book
Access
NEW Springer 2021
Location
Online
In response to the complexity involved in treating leukemia during pregnancy, and the need to find the most efficient treatment possible without harming the fetus, this book offers essential guidelines for institutions and practitioners alike. Pursuing a comprehensive approach, the book addresses a broad range of subjects, including: pregnancy and its characteristics; staging, pathology, morbidity and what to expect in each type of leukemia; chemotherapy for leukemia in pregnant women with comp…
Available Online
View e-Book
Other Authors
Schmidt, Carolina Witchmichen Penteado
Otoni, Kaléu Mormino
Responsibility
Carolina Witchmichen Penteado Schmidt, Kaléu Mormino Otoni, editors
Place of Publication
Cham
Publisher
Springer
Date of Publication
c2021
Physical Description
1 online resource (x, 210 p.) : 4 illus., 2 illus. in color
ISBN
9783030540586
9783030540579 (Print ed.)
9783030540593 (Print ed.)
Subjects (MeSH)
Antineoplastic Agents - therapeutic use
Leukemia - drug therapy
Maternal-Fetal Exchange - drug effects
Pregnancy Complications, Neoplastic
Specialty
Medical Oncology
Obstetrics
Pharmacology
Abstract
In response to the complexity involved in treating leukemia during pregnancy, and the need to find the most efficient treatment possible without harming the fetus, this book offers essential guidelines for institutions and practitioners alike. Pursuing a comprehensive approach, the book addresses a broad range of subjects, including: pregnancy and its characteristics; staging, pathology, morbidity and what to expect in each type of leukemia; chemotherapy for leukemia in pregnant women with complete trials; dose adjustment of chemotherapy for leukemia in pregnancy based on serum dosages; and pharmacokinetics and pharmacodynamics for this unique group of patients. In turn, subsequent chapters focus on protecting the fetus and neonatal management regarding chemotherapy for leukemia in pregnancy, including the treatment and risks for the fetus (for each type of leukemia), intrathecal therapy and its effects on the fetus; supportive drugs, antibiotics and antifungals for pregnant patients during chemotherapy, including intervention and dose adjustments; palliative care for women with leukemia in pregnancy; breastfeeding during treatment for leukemia; pharmacological aspects of supplements, vitamins and nutrition in pregnancy during leukemia treatment; and more. Combining contributions from highly qualified hematology professionals, who have pooled their knowledge to address the treatment of virtually every aspect of leukemia in pregnancy, the book is aimed at a complete pharmacological treatment, including guidelines and trials. It is a must-have not only for institutions providing care for hematology patients, but also for residency programs, research institutions, and professionals in areas that involve leukemia treatment for pregnant women — e.g. hematology, neonatology, obstetrics clinics, intensive medicine and critical care units.
Contents
Introduction -- Clinical Perspectives For Leukemia Treatment During Pregnancy -- Chemotherapy Protocols For Leukemia During Pregnancy -- Pharmacokinetics And Pharmacodynamics Of Chemotherapy For Leukemia In Pregnancy -- Clinical Care Of The Fetus And The Mother: Obstetrics Management For Patients On Treatment For Leukemia -- Antibiotic And Antifungal Therapies During Leukemia Treatment In Pregnancy -- Transfusion In Pregnant Patients Receiving Treatment For Leukemia -- Dose Adjustment Of Chemotherapy For Leukemia In Pregnancy Based On Serum Dosages -- Supportive Drugs in Leukemia Treatment During Pregnancy -- Breastfeeding During Chemotherapy Treatment For Leukemia -- Palliative Care For Patients With Leukemia During Pregnancy.
Access
NEW Springer 2021
Format
e-Book
Location
Online
Less detail

Chemotherapy in Neonates and Infants : Pharmacological Oncology for Children Under 1 Year Old

https://libcat.nshealth.ca/en/permalink/provcat42571
Carolina Witchmichen Penteado Schmidt. --Cham: Springer , c2018.
Available Online
View e-Book
Location
Online
This book provides a comprehensive overview of pediatric oncology, discussing drug therapy and treatment in children under the age of 1 year. It is the first volume to focus on chemotherapy in newborns and infants, especially the daily clinical practice and treatment protocols. Intended as a practical manual, it addresses all the major topics related to pediatric oncology in an accessible and easy-to-use format. It examines topics in pediatric oncology therapeutics, including drug metabolism, e…
Available Online
View e-Book
Author
Penteado Schmidt, Carolina Witchmichen
Responsibility
Carolina Witchmichen Penteado Schmidt
Place of Publication
Cham
Publisher
Springer
Date of Publication
c2018
Physical Description
1 online resource (xix, 198 p.) : 8 illus. in color
ISBN
9783319705910
9783319705903 (print ed.)
9783319705927 (print ed.)
Subjects (MeSH)
Antineoplastic Agents - pharmacology
Drug-Related Side Effects and Adverse Reactions - prevention & control
Infant
Infant, Newborn
Neoplasms - drug therapy
Specialty
Medical Oncology
Pediatrics
Pharmacology
Abstract
This book provides a comprehensive overview of pediatric oncology, discussing drug therapy and treatment in children under the age of 1 year. It is the first volume to focus on chemotherapy in newborns and infants, especially the daily clinical practice and treatment protocols. Intended as a practical manual, it addresses all the major topics related to pediatric oncology in an accessible and easy-to-use format. It examines topics in pediatric oncology therapeutics, including drug metabolism, excretion, toxicity, drugs that can be used for each week or month of the patient's life, dose adjustment and treatment protocols. Chemotherapy in Neonates and Infants focuses on the safe treatment of children in the first year of life, and is aimed at pediatric oncology/hematology institutions, clinics and departments. It is particularly valuable for researchers, pediatric oncology physicians, pediatric and neonatology physicians, oncology pharmacists and the other healthcare professionals directly involved in the chemotherapy of neonates and infants.
Contents
1. Introduction -- 2. Protocols Used in Chemotherapy Treatment of Neonates and Infants -- 3. Pharmacokinetics and Pharmacodynamics of Chemotherapy Drugs in Neonates and Infants -- 4. Peculiarities of Most Commonly Used Chemotherapy Drugs in Neonates and Infants -- 5. Adjuvant Drugs Used in Chemotherapy for Neonates and Infants -- 6. Drug Interactions in Neonates and Infants -- 7. Toxicity -- 8. Tumor Lysis in Neonates and Infants -- 9. Chemotherapy in Neonates and Infants with Cancer and Other Congenital Diseases: Down Syndrome and HIV -- 10. Stem Cell Transplantation in Neonates and Infants.
Format
e-Book
Location
Online
Less detail

Chronic Myeloid Leukemia

https://libcat.nshealth.ca/en/permalink/provcat40239
R©diger Hehlmann, editor. --Cham: Springer , c2016.
Available Online
View e-Book
Location
Online
This book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health. Among the management topics addressed are the choices, advantages, and pitfalls of first-, second-, and third-line treatments; the European LeukemiaNet recommendations; management of adverse effects of tyrosine kinase inhibitors (TKI); management of CML blast crisis; management o…
Available Online
View e-Book
Other Authors
Hehlmann, R©diger
Responsibility
R©diger Hehlmann, editor
Place of Publication
Cham
Publisher
Springer
Date of Publication
c2016
Physical Description
1 online resource (x, 255 p. : 40 illus., 39 illus. in color)
Series
Hematologic Malignancies
Series Title
Hematologic malignancies (Series)
ISBN
9783319331980
9783319331973 (print ed.)
ISSN
2197-9766
Subjects (MeSH)
Antineoplastic Agents - therapeutic use
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology
Abstract
This book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health. Among the management topics addressed are the choices, advantages, and pitfalls of first-, second-, and third-line treatments; the European LeukemiaNet recommendations; management of adverse effects of tyrosine kinase inhibitors (TKI); management of CML blast crisis; management of pregnancy in the context of CML; the role of hematopoietic cell transplantation; the current experience with TKI discontinuation; and the value of interferon in improving the outcome of TKI treatment. Various aspects of relevance to treatment outcome are discussed, including prognostic scores, molecular monitoring (principles and interlaboratory standardization), and response-related predictors of survival. Furthermore, updates are provided on the increasing prevalence of CML and its implications and on the changing cost of care for CML, taking into account the forthcoming impact of availability of generic imatinib.
Contents
1 Cytogenetics of Chronic Myeloid Leukemia (CML) -- 2 The Biology and Pathogenesis of Chronic Myeloid Leukemia -- 3 The Choice of First-Line Chronic Myelogenous Leukemia Treatment -- 4 A Review and an Update of European LeukemiaNet Recommendations for the Management of Chronic Myeloid Leukemia -- 5 Management of Adverse Events Associated with ATP-Competitive BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia -- 6 Standardization of Molecular Monitoring for Chronic Myeloid Leukemia -- 7 Epidemiology of Chronic Myeloid Leukemia -- 8 Prognostic Scores for Patients with Chronic Myeloid Leukemia Under Particular Consideration of Disease-Specific Death -- 9 Response-Related Predictors of Survival in CML -- 10 CML Blast Crisis: Implications and Management -- 11 Managing Pregnancy in Chronic Myeloid Leukemia -- 12 The Role of Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia -- 13 Discontinuation or Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response -- 14 The Interferon Alpha Revival in CML -- 15 Changing the Cost of Care for Chronic Myeloid Leukemia: The Availability of Generic Imatinib in the USA and the EU.
Format
e-Book
Location
Online
Less detail

99 records – page 1 of 5.